Literature DB >> 29607151

Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes.

Satoshi Watanabe1, Keigo Saeki1, Yuko Waseda2, Akari Murata1, Hazuki Takato3, Yukari Ichikawa4, Masahide Yasui5, Hideharu Kimura1, Yasuhito Hamaguchi6, Takashi Matsushita6, Kazunori Yamada7, Mitsuhiro Kawano7, Kengo Furuichi8, Takashi Wada9, Kazuo Kasahara1.   

Abstract

BACKGROUNDS: Lung cancer (LC) adversely impacts survival in patients with idiopathic pulmonary fibrosis. However, little is known about LC in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The aim of this study was to evaluate the prevalence of and risk factors for LC in CTD-ILD, and the clinical characteristics and survival of CTD-ILD patients with LC.
METHODS: We conducted a single-center, retrospective review of patients with CTD-ILD from 2003 to 2016. Patients with pathologically diagnosed LC were identified. The prevalence, risk factors, and clinical features of LC and the impact of LC on CTD-ILD patient outcomes were observed.
RESULTS: Of 266 patients with CTD-ILD, 24 (9.0%) had LC. CTD-ILD with LC was more likely in patients who were older, male, and smokers; had rheumatoid arthritis, a usual interstitial pneumonia pattern, emphysema on chest computed tomography scan, and lower diffusing capacity of the lung carbon monoxide (DLco)% predicted; and were not receiving immunosuppressive therapy. Multivariate analysis indicated that the presence of emphysema [odds ratio (OR), 8.473; 95% confidence interval (CI), 2.241-32.033] and nonuse of immunosuppressive therapy (OR, 8.111; 95% CI, 2.457-26.775) were independent risk factors for LC. CTD-ILD patients with LC had significantly worse survival than patients without LC (10-year survival rate: 28.5% vs. 81.8%, P<0.001).
CONCLUSIONS: LC is associated with the presence of emphysema and nonuse of immunosuppressive therapy, and contributes to increased mortality in patients with CTD-ILD.

Entities:  

Keywords:  Interstitial lung disease (ILD); connective tissue disease (CTD); emphysema; lung cancer (LC)

Year:  2018        PMID: 29607151      PMCID: PMC5864671          DOI: 10.21037/jtd.2017.12.134

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  31 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Authors:  Dinesh Khanna; Shikha Mittoo; Rohit Aggarwal; Susanna M Proudman; Nicola Dalbeth; Eric L Matteson; Kevin Brown; Kevin Flaherty; Athol U Wells; James R Seibold; Vibeke Strand
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

4.  Cumulative incidence of and predictive factors for lung cancer in IPF.

Authors:  Yuichi Ozawa; Takafumi Suda; Tateaki Naito; Noriyuki Enomoto; Dai Hashimoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Hirotoshi Nakamura; Kingo Chida
Journal:  Respirology       Date:  2009-07       Impact factor: 6.424

Review 5.  Association of malignancy with diseases causing interstitial pulmonary changes.

Authors:  Demosthenes Bouros; Kostas Hatzakis; Haris Labrakis; Kyriaki Zeibecoglou
Journal:  Chest       Date:  2002-04       Impact factor: 9.410

6.  Lung cancer associated with usual interstitial pneumonia.

Authors:  H Matsushita; S Tanaka; Y Saiki; M Hara; K Nakata; S Tanimura; J Banba
Journal:  Pathol Int       Date:  1995-12       Impact factor: 2.534

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  The impact of lung cancer on survival of idiopathic pulmonary fibrosis.

Authors:  Sara Tomassetti; Christian Gurioli; Jay H Ryu; Paul A Decker; Claudia Ravaglia; Paola Tantalocco; Matteo Buccioli; Sara Piciucchi; Nicola Sverzellati; Alessandra Dubini; Giampaolo Gavelli; Marco Chilosi; Venerino Poletti
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

10.  Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991.

Authors:  C Wells; D M Mannino
Journal:  South Med J       Date:  1996-05       Impact factor: 0.954

View more
  8 in total

1.  Rituximab in connective tissue disease-associated interstitial lung disease.

Authors:  Ana Catarina Duarte; Ana Cordeiro; Bruno Miguel Fernandes; Miguel Bernardes; Patrícia Martins; Inês Cordeiro; Tânia Santiago; Maria Inês Seixas; Ana Roxo Ribeiro; Maria José Santos
Journal:  Clin Rheumatol       Date:  2019-04-23       Impact factor: 2.980

2.  Real world data of combined lung cancer and interstitial lung disease.

Authors:  Tatsuo Kawahara; Hiroyuki Sakashita; Takafumi Suzuki; Tomoya Tateishi; Yasunari Miyazaki
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

3.  Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.

Authors:  Joo Heung Yoon; Mehdi Nouraie; Xiaoping Chen; Richard H Zou; Jacobo Sellares; Kristen L Veraldi; Jared Chiarchiaro; Kathleen Lindell; David O Wilson; Naftali Kaminski; Timothy Burns; Humberto Trejo Bittar; Samuel Yousem; Kevin Gibson; Daniel J Kass
Journal:  Respir Res       Date:  2018-10-03

4.  Prediction of the 1-Year Risk of Incident Lung Cancer: Prospective Study Using Electronic Health Records from the State of Maine.

Authors:  Xiaofang Wang; Yan Zhang; Shiying Hao; Xuefeng B Ling; Le Zheng; Jiayu Liao; Chengyin Ye; Minjie Xia; Oliver Wang; Modi Liu; Ching Ho Weng; Son Q Duong; Bo Jin; Shaun T Alfreds; Frank Stearns; Laura Kanov; Karl G Sylvester; Eric Widen; Doff B McElhinney
Journal:  J Med Internet Res       Date:  2019-05-16       Impact factor: 5.428

5.  Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study.

Authors:  Won-Il Choi; Dong Yoon Lee; Hyun-Gi Choi; Choong Won Lee
Journal:  Respir Res       Date:  2019-06-10

Review 6.  Scar tissue to lung cancer; pathways and treatment.

Authors:  Konstantinos Sapalidis; Chrysanthi Sardeli; Efstathios Pavlidis; Georgios Koimtzis; Charilaos Koulouris; Nikolaos Michalopoulos; Stylianos Mantalovas; Theodora Tsiouda; Ioannis Passos; Christoforos Kosmidis; Dimitrios Giannakidis; Valeriu Surlin; Athanasios Katsaounis; Vyron Alexandrou; Aikaterini Amaniti; Paul Zarogoulidis; Haidong Huang; Qiang Li; Stelian Mogoanta; Isaac Kesisoglou
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

7.  Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China.

Authors:  Xie Xiaohong; Wang Liqiang; Li Na; Lin Xinqing; Qin Yinyin; Liu Ming; Ouyang Ming; Han Qian; Luo Qun; Li Shiyue; Li Chunyan; Wang Xiaoqian; Yang Shuanying; Huang Wei; Liu Mei; Wang Ping; Zhou Chengzhi
Journal:  Front Mol Biosci       Date:  2021-03-31

Review 8.  Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.

Authors:  Namrata Kewalramani; Carlos Machahua; Venerino Poletti; Jacques Cadranel; Athol U Wells; Manuela Funke-Chambour
Journal:  ERJ Open Res       Date:  2022-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.